NovoCure Limited Stock 12‑Month Price Target Raised to $22.2, Implies 52% Upside
NovoCure Limited's average stock price target increased to $22.2 from $21.33, with a range of $15 to $29, according to 5 analysts. This implies a 52% upside from the Nov. 4 closing price. The consensus rating remains 'Buy' among 6 analysts, with 3 Buys and 3 Holds.
How this was made

The 30-second read
Why it matters
Analyst target revisions can move the stock modestly, but without a new catalyst the effect may be short‑lived.
Market read
Price target update provides a small signal for traders, but limited actionable insight.
What to watch
No new clinical data released; price target change reflects analyst optimism rather than concrete catalyst.
Background
NovoCure is a biotech focused on cancer immunotherapy; its stock is volatile around trial news.
Ticker impact
Analyst consensus price target for NovoCure raised to $22.2, implying ~52% upside from the latest close.
likely upward pressure as investors price in the higher target
Five analysts increased their median target; no new corporate event, just revised expectations.
Market effects
May lift sentiment in the oncology biotech sector.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
Target raise could be premature if upcoming trial data disappoint.
Key entities
- CompanyNovoCure Limited
Biotech firm developing immunotherapy treatments.

